Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02895880 · ClinicalTrials.gov registry record
A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 49
- Enrollment target
NCT02895880: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02895880 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02895880 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to collect initial data on what survivors of childhood, adolescent, and young adult cancer think of how information about statins is communicated. Statins are medications that lower cholesterol. The results of this study will be used to improve the communication about statins. This is to aid patients and their providers in making health care decisions together, also known as shared decision making.
Interventions
- BEHAVIORAL usual care
- BEHAVIORAL statin communication tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-06-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02895880
The ClinicalTrials.gov registry entry for NCT02895880 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which usual care is the first listed.
NCT02895880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02895880 about?
NCT02895880 is a clinical study titled "A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing". The purpose of this study is to collect initial data on what survivors of childhood, adolescent, and young adult cancer think of how information about statins is communicated. Statins are medications that lower cholesterol. The results of this study will be used to improve the communication about st...
What is the current status of trial NCT02895880?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2016-08. Estimated completion is 2020-06-11.
What interventions are being tested in trial NCT02895880?
The interventions under investigation include: usual care (BEHAVIORAL), statin communication tool (BEHAVIORAL).
Who is sponsoring clinical trial NCT02895880?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.